Nemaura Medical to Present at the LD Micro Main Event Conference

Rhea-AI Summary

Nemaura Medical (NASDAQ: NMRD) has announced that CEO Faz Chowdhury, Ph.D., will present virtually at the 14th Annual LD Micro Main Event Conference on October 13 at 10:00 AM ET. The presentation aims to provide insights into Nemaura's advancements in non-invasive wearable diagnostic devices, including the sugarBEAT® and proBEAT™ products. Nemaura operates within the rapidly expanding global Type 2 diabetes and wearable health-tech markets, which are projected to reach substantial valuations in coming years.

Loughborough, England, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces today that Chief Executive Officer Faz Chowdhury, Ph.D. will be presenting virtually at the 14^th Annual LD Micro Main Event Conference.

Dr. Chowdhury will deliver his corporate presentation on October 13 at 10:00 AM ET.

Register to watch the presentation here.

About Nemaura Medical, Inc.

Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT^® and proBEAT^™. sugarBEAT^®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT^® to the U.S. FDA. proBEAT^™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT^®diabetes program.

The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.

For more information, please visit www.NemauraMedical.com.

Contact:

Jules Abraham
CORE IR
917-885-7378
julesa@coreir.com

FAQ

When will Nemaura Medical's CEO present at the LD Micro Main Event Conference?

CEO Faz Chowdhury will present virtually on October 13 at 10:00 AM ET.

What products is Nemaura Medical focusing on in their presentation?

Nemaura Medical is focusing on their non-invasive wearable devices, including sugarBEAT® and proBEAT™.

What is the significance of the sugarBEAT® device?

sugarBEAT® is a CE mark approved Class IIb medical device that provides continuous glucose monitoring for diabetes management.

What markets does Nemaura Medical operate in?

Nemaura Medical operates in the global Type 2 diabetes market, the pre-diabetic market, and the wearable health-tech sector.

How is Nemaura Medical addressing the diabetes epidemic?

Nemaura Medical is developing solutions like sugarBEAT® to help manage and prevent diabetes through innovative technology.